Bruceantin targets HSP90 to overcome resistance to hormone therapy in castration-resistant prostate cancer

Conclusion: Our findings suggest that BCT could serve as a promising therapeutic candidate against CRPC and highlight the potential benefit of targeting AR-FL/AR-V7-HSP90 axis to overcome resistance caused by aberrant AR-FL/AR-V7 signaling.

Source: Theranostics - January 15, 2021 Category: Molecular Biology Authors: Sue Jin Moon, Byong Chang Jeong, Hwa Jin Kim, Joung Eun Lim, Hye-Jeong Kim, Ghee Young Kwon, Joshua A. Jackman, Jeong Hoon Kim Tags: Research Paper Source Type: research